|
|
| |
LifeCycle Pharma has a pipeline of late-stage development projects. Shares in the company are traded on the Copenhagen stock exchange. |
|
www.lifecyclepharma.com |
|
|
|
|
| |
Curalogic is a publically listed biotechnology company re-establishing a development pipeline. Shares of the company are traded on the Copenhagen stock exchange. |
 |
www.curalogic.com |
|
|
|
|
| |
Rose Pharma develops of drugs based on ghrelin and GLP-1 for various indications. The company was based on clinical know-how from the Sahlgrenska University, Göteborg. |
|
www.rosepharma.com |
|
|
|
|
|
Osteologix, Inc. develops drugs for bone and cartilage diseases, notably osteoporosis. The company is in clinical phase II with its lead osteoporosis drug. Shares of Osteologix are traded on the bulletin board under the ticker OLGX.OB. |
|
www.osteologix.com |
|
|
|
|
| |
Forward Pharma develops immunomodulatory drugs for the treatment of a range of common disorders. Forward Pharma's main focus is dermatology, but several other important disease areas are also part of the development plan. |
|
www.forward-pharma.com |
|
|
|
|
| |
Biotica Technology Ltd. Improves commercially significant polyketide drugs. It has a strategic collaboration with Wyeth for certain drug classes. The company was founded based on science by Prof. Dr. Peter Leadlay and Prof. Dr. Jim Staunton, Cambridge University. |
|
www.biotica.com |
|
|
|
|
| |
Aditech AB owns intellectual property in the fields of inflammatory, bone, cartilage and GI diseases. It has out-licensed certain rights to other companies against future royalty payments. The company also develops peptide therapeutics for various disorders. |
|
|
|
|
|
|
